A patient who has completed the intensive phase of tuberculosis therapy develops an allergic reaction to the continuation‑phase regimen of isoniazid and rifampicin; how should the treatment be adjusted?

Management of Allergic Reaction to Continuation-Phase HR in Tuberculosis

If a patient develops an allergic reaction to the 4-month isoniazid-rifampin (HR) continuation phase after completing the intensive phase, immediately stop both drugs and determine which specific drug is responsible through sequential reintroduction testing, then construct an alternative regimen based on the culprit drug identified. 1

Immediate Management

• Stop all antituberculosis drugs immediately when an allergic reaction occurs 1
• If the patient is not severely ill and has non-infectious disease (sputum smear-negative), no treatment is required while awaiting resolution of the allergic reaction 1
• If the patient is unwell or sputum smear-positive, temporary treatment with streptomycin and ethambutol should be given until the allergic reaction resolves, unless clinically contraindicated or drug resistance is suspected 1

Sequential Drug Reintroduction Protocol

Once the allergic reaction has completely resolved, drugs should be reintroduced sequentially with daily clinical monitoring and liver function testing to identify the culprit agent 1:

Reintroduction Sequence (in this specific order):

1. Isoniazid first:

   • Start at 50 mg/day
   • Increase to 300 mg/day after 2-3 days if no reaction
   • Continue for 2-3 days at full dose 1

2. Rifampin second (only if isoniazid tolerated):

   • Start at 75 mg/day
   • Increase to 300 mg after 2-3 days
   • Then increase to 450 mg (<50 kg) or 600 mg (>50 kg) after another 2-3 days 1

3. Monitor closely for recurrence of allergic symptoms during each step 1

Alternative Regimens Based on Culprit Drug

If Isoniazid is the Culprit:

• Continue rifampin with ethambutol for the remainder of treatment
• Total treatment duration should be 9 months (including the initial intensive phase) 2
• Rifampin and ethambutol should be given for 7 months in the continuation phase 2

If Rifampin is the Culprit:

• Continue isoniazid with ethambutol for an extended duration
• Consider adding a fluoroquinolone (such as ofloxacin or moxifloxacin) as a second-line agent 3, 4
• Total treatment duration should be at least 9 months, potentially extending to 12-18 months depending on clinical response 3
• This is a less favorable scenario as rifampin is the most potent sterilizing drug 2

If Both Drugs Cannot Be Tolerated:

• Expert consultation is mandatory 1
• Consider a regimen with isoniazid, streptomycin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid, streptomycin, and pyrazinamide for 7 months (total 9 months) 3
• Alternative: Use second-line drugs including fluoroquinolones and injectable agents under specialist supervision 3, 4

Desensitization Option

If the culprit drug is essential and no adequate alternatives exist:

• Desensitization protocols can be attempted with success rates of approximately 79-83% for rifampin and isoniazid respectively 5, 6
• Desensitization must be performed under cover of two other antituberculosis drugs to prevent emergence of resistance 1
• Recent data shows rapid desensitization protocols have overall success rates of 95%, though breakthrough reactions occur in approximately 42% of patients (mostly mild) 6
• Desensitization should be performed in a monitored setting with immediate access to emergency medications 7, 8, 6

Critical Pitfalls to Avoid

• Never use monotherapy or inadequate dual therapy during the diagnostic workup, as this risks developing drug resistance 1
• Do not assume the reaction is to both drugs without sequential testing—often only one drug is responsible 1, 9
• Avoid three-drug regimens without a rifamycin, aminoglycoside, or capreomycin for less than 18 months, as these have inferior outcomes 3
• Do not restart drugs simultaneously—sequential reintroduction is essential to identify the specific culprit 1